Get the Stockscreener App
44.40
0.87%
0.385
Exelixis Inc stock is traded at $44.40, with a volume of 1.51M.
It is up +0.87% in the last 24 hours and up +17.14% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$44.01
Open:
$43.97
24h Volume:
1.51M
Relative Volume:
0.56
Market Cap:
$11.90B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
25.08
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
+0.42%
1M Performance:
+17.14%
6M Performance:
+5.15%
1Y Performance:
+24.11%
1-Day Range:
$43.95
$44.79
1-Week Range:
$43.00
$44.91
52-Week Range:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.40 | 11.80B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Will Exelixis Inc. (EX9) stock outperform energy sector in 2025Profit Target & Daily Technical Stock Forecast Reports - Newser
Will Exelixis Inc. (EX9) stock beat Nasdaq index returns2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
How forex fluctuations impact Exelixis Inc. (EX9) stockRisk Management & Weekly Stock Performance Updates - Newser
Will Exelixis Inc. (EX9) stock profit from automation wave2025 Analyst Calls & Technical Confirmation Trade Alerts - Newser
Why Exelixis Inc. (EX9) stock appeals to dividend investorsTreasury Yields & AI Forecasted Stock Moves - Newser
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report? - Yahoo Finance
Will Exelixis Inc. (EX9) stock rise with strong economyWeekly Stock Summary & Smart Money Movement Alerts - Newser
How Exelixis Inc. (EX9) stock compares with top peers2025 Market Overview & Safe Entry Momentum Stock Tips - Newser
Can Exelixis Inc. (EX9) stock beat analyst consensusWeekly Profit Analysis & Reliable Breakout Stock Forecasts - Newser
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 - Business Wire
Exelixis (NASDAQ:EXEL) shareholders have earned a 39% CAGR over the last three years - Yahoo Finance
Vascular Endothelial Growth Factor Receptor (VEGFR) - openPR.com
Will Exelixis Inc. stock attract more institutional investorsJuly 2025 Outlook & Short-Term Trading Alerts - Newser
Is Exelixis Inc. stock a buy for dividend growthWall Street Watch & Free Community Supported Trade Ideas - Newser
How Exelixis Inc. (EX9) stock trades under stagflationQuarterly Performance Summary & Fast Entry and Exit Trade Plans - Newser
Will Exelixis Inc. (EX9) stock announce a stock split2025 Earnings Impact & Weekly Top Gainers Trade List - Newser
Can Exelixis Inc. (EX9) stock retain market dominanceRate Cut & Daily Risk Controlled Trade Plans - Newser
2 Under-the-Radar Stocks to Buy Heading Into 2026 - Finviz
2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
EXEL (Exelixis) Earnings Yield (Joel Greenblatt) % : 7.99% (As of Sep. 2025) - GuruFocus
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK
Here's Why Exelixis (EXEL) is a Strong Growth Stock - MSN
EXEL (Exelixis) Cash, Cash Equivalents, Marketable Securities : $989 Mil (As of Sep. 2025) - GuruFocus
EXEL (Exelixis) Total Assets : $2,824 Mil (As of Sep. 2025) - GuruFocus
Hedge Fund and Insider Trading News: Ray Dalio, Michael Burry, Marshall Wace, Exelixis Inc (EXEL), Monolithic Power Systems Inc (MPWR), and More - Insider Monkey
Exelixis (LTS:0IJO) FCF Yield % : 6.28 (As of Nov. 28, 2025) - GuruFocus
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners - MSN
How (EXEL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Exelixis Inc Stock Analysis and ForecastProtective Put Strategies & Budget Friendly Trading Strategies - earlytimes.in
Aug Rallies: How Exelixis Inc. stock reacts to job market dataQuarterly Market Review & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
Exelixis (EXEL) Director Invests $1.2 Million in Company Stock - GuruFocus
Dir Johnson Buys 27,532 ($1.2M) Of Exelixis Inc [EXEL] - TradingView
Caligan-linked Exelixis director reports 27,532-share EXEL purchase - Stock Titan
Exelixis, Inc.Common Stock (NQ: EXEL - Markets Financial Content
Exelixis EVP Haley sells shares worth $3m By Investing.com - Investing.com South Africa
Exelixis Insider Sold Shares Worth $3,046,928, According to a Recent SEC Filing - marketscreener.com
EDGAR Filing Documents for 0000939767-25-000127 - SEC.gov
EXEL insider Form 4: EVP gifts 24,000 Exelixis shares - Stock Titan
Exelixis EVP Haley sells shares worth $3m - Investing.com
VP Aftab Gifts 24,000 Of Exelixis Inc [EXEL] - TradingView
Exelixis EVP Patrick J. Haley Sells Over $3 Million in Company Stock - TradingView
EXELIXIS INC (1EXEL.MI) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Exelixis Is Focusing On Neuroendocrine Tumors — But Is a $100 Million Windfall Next? - Smartkarma
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D - MSN
[Form 3] EXELIXIS, INC. Initial Statement of Beneficial Ownership - Stock Titan
Why Exelixis Inc. stock attracts high net worth investorsQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Will Exelixis Inc. stock sustain high P E ratios2025 Year in Review & Long-Term Capital Growth Ideas - newser.com
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):